GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cascadian Therapeutics Inc (NAS:CASC) » Definitions » Asset Turnover

Cascadian Therapeutics (Cascadian Therapeutics) Asset Turnover : 0.00 (As of Dec. 2017)


View and export this data going back to 1991. Start your Free Trial

What is Cascadian Therapeutics Asset Turnover?

Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Cascadian Therapeutics's Revenue for the three months ended in Dec. 2017 was $0.00 Mil. Cascadian Therapeutics's Total Assets for the quarter that ended in Dec. 2017 was $127.11 Mil. Therefore, Cascadian Therapeutics's Asset Turnover for the quarter that ended in Dec. 2017 was 0.00.

Asset Turnover is linked to ROE % through Du Pont Formula. Cascadian Therapeutics's annualized ROE % for the quarter that ended in Dec. 2017 was -57.39%. It is also linked to ROA % through Du Pont Formula. Cascadian Therapeutics's annualized ROA % for the quarter that ended in Dec. 2017 was -52.75%.


Cascadian Therapeutics Asset Turnover Historical Data

The historical data trend for Cascadian Therapeutics's Asset Turnover can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cascadian Therapeutics Asset Turnover Chart

Cascadian Therapeutics Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
Asset Turnover
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Cascadian Therapeutics Quarterly Data
Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17
Asset Turnover Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cascadian Therapeutics's Asset Turnover

For the Biotechnology subindustry, Cascadian Therapeutics's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cascadian Therapeutics's Asset Turnover Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cascadian Therapeutics's Asset Turnover distribution charts can be found below:

* The bar in red indicates where Cascadian Therapeutics's Asset Turnover falls into.



Cascadian Therapeutics Asset Turnover Calculation

Asset Turnover measures how quickly a company turns over its asset through sales.

Cascadian Therapeutics's Asset Turnover for the fiscal year that ended in Dec. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (A: Dec. 2017 )/( (Total Assets (A: Dec. 2016 )+Total Assets (A: Dec. 2017 ))/ count )
=0/( (83.265+120.825)/ 2 )
=0/102.045
=0.00

Cascadian Therapeutics's Asset Turnover for the quarter that ended in Dec. 2017 is calculated as

Asset Turnover
=Revenue/Average Total Assets
=Revenue (Q: Dec. 2017 )/( (Total Assets (Q: Sep. 2017 )+Total Assets (Q: Dec. 2017 ))/ count )
=0/( (133.387+120.825)/ 2 )
=0/127.106
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.


Cascadian Therapeutics  (NAS:CASC) Asset Turnover Explanation

Asset Turnover is linked to ROE % through Du Pont Formula.

Cascadian Therapeutics's annulized ROE % for the quarter that ended in Dec. 2017 is

ROE %**(Q: Dec. 2017 )
=Net Income/Total Stockholders Equity
=-67.048/116.826
=(Net Income / Revenue)*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-67.048 / 0)*(0 / 127.106)*(127.106/ 116.826)
=Net Margin %*Asset Turnover*Equity Multiplier
= %*0*1.088
=ROA %*Equity Multiplier
=-52.75 %*1.088
=-57.39 %

Note: The Net Income data used here is four times the quarterly (Dec. 2017) net income data. The Revenue data used here is four times the quarterly (Dec. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.

It is also linked to ROA % through Du Pont Formula:

Cascadian Therapeutics's annulized ROA % for the quarter that ended in Dec. 2017 is

ROA %(Q: Dec. 2017 )
=Net Income/Total Assets
=-67.048/127.106
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-67.048 / 0)*(0 / 127.106)
=Net Margin %*Asset Turnover
= %*0
=-52.75 %

Note: The Net Income data used here is four times the quarterly (Dec. 2017) net income data. The Revenue data used here is four times the quarterly (Dec. 2017) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.


Cascadian Therapeutics Asset Turnover Related Terms

Thank you for viewing the detailed overview of Cascadian Therapeutics's Asset Turnover provided by GuruFocus.com. Please click on the following links to see related term pages.


Cascadian Therapeutics (Cascadian Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
Cascadian Therapeutics Inc is a clinical-stage biopharmaceutical company focusing in developing innovative therapeutic product candidates for the treatment of cancer. Its objective is to discover, develop and commercialize novel compounds that have the potential to improve the lives and outcomes of cancer patients. The company's clinical-stage product candidate includes ONT-380, an orally active and selective small molecule HER2 inhibitor. In addition, it is also engaged in developing preclinical product candidates in oncology using its Checkpoint kinase 1 kinase inhibitor and protocell technology. All the business activity of the firm is functioned through the region of United States.
Executives
Ted W Love director C/O GLOBAL BLOOD THERAPEUTICS, INC., 400 EAST JAMIE COURT, SUITE 101, SOUTH SAN FRANCISCO CA 94080
Gwen A. Fyfe director C/O ARRAY BIOPHARMA INC., 3200 WALNUT STREET, BOULDER CO 80301
Steven P James director C/O OCERA THERAPUETICS, 525 UNIVERSITY AVENUE, SUITE 610, PALO ALTO CA 94301
Julia Marie Eastland officer: CFO & CBO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Christopher S Henney director 10505 ROSELLE STREET, SAN DIEGO CA 92121
Robert Azelby director 307 WESTLAKE AVE. NORTH, STE 300, SEATTLE WA 98109
Daniel K Spiegelman director MYRIAD GENETICS, 320 WAKARA WAY, SALT LAKE CITY UT 84003
Scott Dunseth Myers director, officer: President and CEO C/O CASCADIAN THERAPEUTICS, INC., 3101 WESTERN AVE., SUITE 600, SEATTLE WA 98121
Growth Equity Opportunities Iv, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea 15 Gp, Llc 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Nea Partners 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
New Enterprise Associates 15, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Jon Sakoda 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025
Florence Anthony A. Jr. 10 percent owner 5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Peter W. Sonsini 10 percent owner 2855 SAND HILL ROAD, MENLO PARK CA 94025

Cascadian Therapeutics (Cascadian Therapeutics) Headlines

From GuruFocus

Seth Klarman Buys 25 Million Shares of Cascadian Therapeutics

By Kyle Ferguson Kyle Ferguson 07-11-2016